PSMD1 and neoplasm: Peptide vaccine combined with chemotherapy drugs; dendritic vaccines combined with lymphokine-activated killer cells, gemcitabine and/or S-1, and DCs immunotherapy combined with Toll-like receptor (TLR)-3 agonists, etc. In order to fully exert the potential efficacy of tumor vaccines, it is necessary to design a multi-antigen combination vaccine that covers a variety of tumor-specific antigens and improves the broad spectrum of the vaccine.